Development and Commercialization Plan. The Parties acknowledge and agree that Ruthigen’s Development and Commercialization shall not include any activities related to dermatological uses or uses related to the Indications. Any references to the OOS Option, the Indications or any product or service outside the definition of Invasive in the Development and Commercialization Plan are hereby deleted.
Appears in 2 contracts
Sources: License and Supply Agreement (Ruthigen, Inc.), License and Supply Agreement (Oculus Innovative Sciences, Inc.)